[Form 4] DAKTRONICS INC /SD/ Insider Trading Activity
Jose-Marie Griffiths, a director of Daktronics, acquired 3,535 shares of common stock on 09/15/2025 at $24.04 per share, increasing her direct beneficial ownership to 61,030 shares. The acquisition is recorded as restricted stock that vests one year from the grant date, indicating the shares are subject to time-based vesting and not immediately transferable. The Form 4 shows the reporting person filed as an individual director and discloses no derivative transactions.
This filing documents an insider purchase rather than a sale, which can signal confidence by management, but the form does not provide company financial results or further context on the grant's purpose.
- Director acquisition: Jose-Marie Griffiths acquired 3,535 shares, increasing her direct ownership to 61,030 shares.
- Alignment with shareholders: Shares are time-vesting restricted stock that vests in one year, which aligns director incentives with long-term performance.
- None.
Insights
TL;DR: Director purchased restricted stock increasing direct ownership to 61,030 shares; vests in one year.
The Form 4 reports a non-derivative acquisition of 3,535 common shares at $24.04 each reported by director Jose-Marie Griffiths on 09/15/2025. These shares are restricted and vest one year from grant, which limits immediate liquidity and aligns the director with shareholder interests over a retention period. The disclosure is routine for equity compensation and does not include derivative activity or indications of changes in control. Without dollar value relative to company market cap or additional insider patterns, the transaction is informative but not clearly material on its own.
TL;DR: Time-vesting restricted stock awarded to a director; standard governance alignment, no immediate transferability.
The grant structure—restricted stock vesting after one year—follows common governance practice to retain executives/directors and align incentives with long-term performance. The filing confirms individual, not joint, reporting and shows no sales or derivative exercises that might raise liquidity or dilution concerns. This disclosure is consistent with routine compensation and compliance with Section 16 reporting requirements.